NCT07779668Not yet recruiting
AI-Driven Health Management to Prevent Ischemic Stroke in High-Risk Adults
Intelligent Early Warning of Ischemic Cerebrovascular Disease Based on Multi-Source Data Fusion and Demonstration of Tiered Prevention and Control in Beijing
Source: ClinicalTrials.gov · Last updated 2 Sept 2026
Brief summary (registry, in English)
This study will evaluate whether an artificial intelligence (AI)-driven dynamic health management strategy can help prevent ischemic stroke in adults at high risk of stroke. Participants will be identified through community-based screening in Beijing using the AI-ExpoStroke model together with established stroke risk factors. Communities will be randomly assigned to either an AI-driven health management group or a usual community-based health management group. Participants in the AI-driven group will receive continuous health management supported by a digital platform, mobile applications or WeChat-based tools, wearable-device data when available, personalized health guidance, and remote support from community health care providers. Participants in the usual-care group will receive routine community health services, including health examinations, health education, chronic disease follow-up, and medication guidance. Participants will be followed for 36 months. The main goal is to determine whether AI-driven health management reduces the occurrence of first-ever ischemic stroke. The study will also evaluate transient ischemic attacks, stroke-related disability, mortality, control of major vascular risk factors, adherence to health management, and health economic outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 26000 (estimated)
- First submitted
- 18 Aug 2026
- Start date
- 31 Aug 2026
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Xuanwu Hospital, Beijing
- Diseases
- Stroke
- NCT number
- NCT07779668
What you commit to
- Study type: Interventional
- Planned participants: 26000
- From 31 Aug 2026 to the primary completion date, 31 Dec 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous diagnosis of ischemic stroke or hemorrhagic stroke.
Other illness
- Severe cognitive impairment.
- Severe organic disease, including malignant tumors, New York Heart Association (NYHA) class III or higher heart failure, renal failure, or other severe conditions.
- Psychiatric or language impairment that prevents completion of study questionnaires or follow-up.
Other
- Inability to obtain complete follow-up data or unwillingness to permit access to relevant study data.
Who the study is looking for
- Age 30 years or older, with no restriction on sex.
- Permanent resident of Beijing.
- No previously diagnosed stroke based on prospective community screening.
- Identified as being at high risk of stroke by the AI-ExpoStroke model in combination with the established stroke "8+2" high-risk factors.
- Able to comply with study follow-up and willing to provide informed consent.
Age in the registry: 30 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.